vs
Arcellx, Inc.（ACLX）与碧迪（BDX）财务数据对比。点击上方公司名可切换其他公司
碧迪的季度营收约是Arcellx, Inc.的3175.3倍（$5.3B vs $1.7M）。碧迪净利率更高（7.3% vs -3513.4%，领先3520.7%）。碧迪同比增速更快（-0.4% vs -89.2%）。碧迪自由现金流更多（$549.0M vs $-58.9M）。过去两年碧迪的营收复合增速更高（2.0% vs -79.5%）
Arcellx, Inc.是一家处于临床阶段的生物技术企业，专注开发用于治疗血液恶性肿瘤、实体瘤等难治性癌症的CAR-T细胞疗法，其核心管线针对肿瘤领域未被满足的医疗需求，服务全球患者群体。
碧迪（Becton Dickinson）是美国跨国医疗科技企业，核心业务包括研发、生产及销售医用器械、仪器系统与试剂产品，同时在特定领域提供专业咨询及数据分析服务，业务覆盖全球多国，在全球医疗技术领域具备领先地位。
ACLX vs BDX — 直观对比
营收规模更大
BDX
是对方的3175.3倍
$1.7M
营收增速更快
BDX
高出88.8%
-89.2%
净利率更高
BDX
高出3520.7%
-3513.4%
自由现金流更多
BDX
多$607.9M
$-58.9M
两年增速更快
BDX
近两年复合增速
-79.5%
损益表 — Q4 2025 vs Q1 2026
| 指标 | | |
|---|---|---|
| 营收 | $1.7M | $5.3B |
| 净利润 | $-58.1M | $382.0M |
| 毛利率 | — | 45.9% |
| 营业利润率 | -3850.2% | 10.5% |
| 净利率 | -3513.4% | 7.3% |
| 营收同比 | -89.2% | -0.4% |
| 净利润同比 | -23.4% | 24.0% |
| 每股收益（稀释后） | $-1.01 | $1.34 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ACLXBDX
| Q4 25 | $1.7M | $5.3B | ||
| Q3 25 | $4.9M | $5.9B | ||
| Q2 25 | $7.6M | $5.5B | ||
| Q1 25 | $8.1M | $5.3B | ||
| Q4 24 | $15.3M | $5.2B | ||
| Q3 24 | $26.0M | $5.4B | ||
| Q2 24 | $27.4M | $5.0B | ||
| Q1 24 | $39.3M | $5.0B |
净利润ACLXBDX
| Q4 25 | $-58.1M | $382.0M | ||
| Q3 25 | $-55.8M | $493.0M | ||
| Q2 25 | $-52.8M | $574.0M | ||
| Q1 25 | $-62.3M | $308.0M | ||
| Q4 24 | $-47.1M | $303.0M | ||
| Q3 24 | $-25.9M | $400.0M | ||
| Q2 24 | $-27.2M | $487.0M | ||
| Q1 24 | $-7.2M | $537.0M |
毛利率ACLXBDX
| Q4 25 | — | 45.9% | ||
| Q3 25 | — | 47.5% | ||
| Q2 25 | — | 47.8% | ||
| Q1 25 | — | 42.8% | ||
| Q4 24 | — | 43.2% | ||
| Q3 24 | — | 45.7% | ||
| Q2 24 | — | 46.2% | ||
| Q1 24 | — | 45.7% |
营业利润率ACLXBDX
| Q4 25 | -3850.2% | 10.5% | ||
| Q3 25 | -1248.3% | 11.8% | ||
| Q2 25 | -777.4% | 16.0% | ||
| Q1 25 | -847.6% | 10.4% | ||
| Q4 24 | -348.2% | 8.8% | ||
| Q3 24 | -129.1% | 11.4% | ||
| Q2 24 | -127.8% | 12.1% | ||
| Q1 24 | -40.3% | 14.5% |
净利率ACLXBDX
| Q4 25 | -3513.4% | 7.3% | ||
| Q3 25 | -1127.1% | 8.4% | ||
| Q2 25 | -698.6% | 10.4% | ||
| Q1 25 | -766.0% | 5.8% | ||
| Q4 24 | -308.4% | 5.9% | ||
| Q3 24 | -99.4% | 7.4% | ||
| Q2 24 | -99.3% | 9.8% | ||
| Q1 24 | -18.3% | 10.6% |
每股收益（稀释后）ACLXBDX
| Q4 25 | $-1.01 | $1.34 | ||
| Q3 25 | $-0.99 | $1.71 | ||
| Q2 25 | $-0.94 | $2.00 | ||
| Q1 25 | $-1.13 | $1.07 | ||
| Q4 24 | $-0.87 | $1.04 | ||
| Q3 24 | $-0.48 | $1.37 | ||
| Q2 24 | $-0.51 | $1.68 | ||
| Q1 24 | $-0.14 | $1.85 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $450.3M | $740.0M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $402.4M | $25.3B |
| 总资产 | $604.0M | $54.8B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资ACLXBDX
| Q4 25 | $450.3M | $740.0M | ||
| Q3 25 | $461.4M | $641.0M | ||
| Q2 25 | $453.1M | $735.0M | ||
| Q1 25 | $543.3M | $667.0M | ||
| Q4 24 | $587.4M | $711.0M | ||
| Q3 24 | $574.3M | $1.7B | ||
| Q2 24 | $516.7M | $4.5B | ||
| Q1 24 | $573.9M | $2.3B |
股东权益ACLXBDX
| Q4 25 | $402.4M | $25.3B | ||
| Q3 25 | $440.8M | $25.4B | ||
| Q2 25 | $392.2M | $25.5B | ||
| Q1 25 | $416.9M | $25.2B | ||
| Q4 24 | $454.8M | $25.2B | ||
| Q3 24 | $483.0M | $25.9B | ||
| Q2 24 | $487.2M | $25.9B | ||
| Q1 24 | $496.6M | $25.6B |
总资产ACLXBDX
| Q4 25 | $604.0M | $54.8B | ||
| Q3 25 | $655.9M | $55.3B | ||
| Q2 25 | $619.1M | $54.9B | ||
| Q1 25 | $648.1M | $54.5B | ||
| Q4 24 | $711.3M | $54.7B | ||
| Q3 24 | $764.9M | $57.3B | ||
| Q2 24 | $734.3M | $55.6B | ||
| Q1 24 | $779.7M | $54.2B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-58.2M | $657.0M |
| 自由现金流经营现金流 - 资本支出 | $-58.9M | $549.0M |
| 自由现金流率自由现金流/营收 | -3563.4% | 10.5% |
| 资本支出强度资本支出/营收 | 46.2% | 2.1% |
| 现金转化率经营现金流/净利润 | — | 1.72× |
| 过去12个月自由现金流最近4个季度 | $-212.6M | $2.6B |
8季度趋势，按日历期对齐
经营现金流ACLXBDX
| Q4 25 | $-58.2M | $657.0M | ||
| Q3 25 | $-49.2M | $1.4B | ||
| Q2 25 | $-39.7M | $1.2B | ||
| Q1 25 | $-63.1M | $164.0M | ||
| Q4 24 | $-46.0M | $693.0M | ||
| Q3 24 | $30.7M | $1.2B | ||
| Q2 24 | $-36.2M | $1.3B | ||
| Q1 24 | $-31.9M | $514.0M |
自由现金流ACLXBDX
| Q4 25 | $-58.9M | $549.0M | ||
| Q3 25 | $-49.5M | $1.0B | ||
| Q2 25 | $-40.2M | $1.0B | ||
| Q1 25 | $-63.9M | $35.0M | ||
| Q4 24 | $-47.5M | $588.0M | ||
| Q3 24 | $28.4M | $882.0M | ||
| Q2 24 | $-39.5M | $1.1B | ||
| Q1 24 | $-38.3M | $380.0M |
自由现金流率ACLXBDX
| Q4 25 | -3563.4% | 10.5% | ||
| Q3 25 | -1000.3% | 17.0% | ||
| Q2 25 | -532.4% | 19.0% | ||
| Q1 25 | -786.4% | 0.7% | ||
| Q4 24 | -311.3% | 11.4% | ||
| Q3 24 | 109.2% | 16.2% | ||
| Q2 24 | -144.1% | 22.4% | ||
| Q1 24 | -97.7% | 7.5% |
资本支出强度ACLXBDX
| Q4 25 | 46.2% | 2.1% | ||
| Q3 25 | 6.0% | 6.0% | ||
| Q2 25 | 6.4% | 3.2% | ||
| Q1 25 | 9.6% | 2.4% | ||
| Q4 24 | 9.8% | 2.0% | ||
| Q3 24 | 8.8% | 5.4% | ||
| Q2 24 | 11.7% | 3.6% | ||
| Q1 24 | 16.4% | 2.7% |
现金转化率ACLXBDX
| Q4 25 | — | 1.72× | ||
| Q3 25 | — | 2.75× | ||
| Q2 25 | — | 2.12× | ||
| Q1 25 | — | 0.53× | ||
| Q4 24 | — | 2.29× | ||
| Q3 24 | — | 2.94× | ||
| Q2 24 | — | 2.66× | ||
| Q1 24 | — | 0.96× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ACLX
暂无分部数据
BDX
| Other | $2.8B | 53% |
| Medication Management Solutions | $678.0M | 13% |
| Urologyand Critical Care | $339.0M | 6% |
| Surgery | $310.0M | 6% |
| Peripheral Intervention | $265.0M | 5% |
| Specimen Management | $245.0M | 5% |
| Advanced Patient Monitoring | $178.0M | 3% |
| Diagnostic Solutions | $176.0M | 3% |
| Bio Pharma Systems | $150.0M | 3% |
| Biosciences | $124.0M | 2% |
